Free Trial
NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Price, News & Analysis

Kiromic BioPharma logo

About Kiromic BioPharma Stock (NASDAQ:KRBP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.21
$1.66
52-Week Range
N/A
Volume
107,749 shs
Average Volume
11,347 shs
Market Capitalization
$330 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

KRBP Stock News Headlines

KRBPQ Kiromic BioPharma, Inc.
Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Kiromic BioPharma Files for Chapter 7 Bankruptcy
Kiromic says Deltacel-01 trial patient reaches progression-free survival
See More Headlines

KRBP Stock Analysis - Frequently Asked Questions

Kiromic BioPharma, Inc. (NASDAQ:KRBP) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.65) EPS for the quarter.

Shares of Kiromic BioPharma reverse split on the morning of Monday, March 13th 2023.The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Kiromic BioPharma (KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.

Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiromic BioPharma investors own include Athenex (ATNX), KLX Energy Services (KLXE), Brainstorm Cell Therapeutics (BCLI), NGL Energy Partners (NGL), Orchard Therapeutics (ORTX), TherapeuticsMD (TXMD) and Achilles Therapeutics (ACHL).

Company Calendar

Last Earnings
11/08/2024
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KRBP
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.90 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($8.29) per share
Price / Book
N/A

Miscellaneous

Free Float
1,217,000
Market Cap
$330 thousand
Optionable
Not Optionable
Beta
1.66
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:KRBP) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners